Compare Amgen, Inc. (AMGN) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? Amgen, Inc. trades at $358.74 (market cap $196.12B), while Hilton Hotels Corporation Common Stock trades at $331.5 (market cap $76.37B). The key difference: Amgen, Inc. is far larger — about 2.6× Hilton Hotels Corporation Common Stock's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | HLT | |
|---|---|---|
Market Cap | $196.12B | $76.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $350.22 |
52-Week Low | $271.18 | $256.75 |
Enterprise Value | $241.41B | $88.87B |
Dividend Yield | 2.77% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Hilton Worldwide (HLT) trades at $335.48, down 0.64% on the day, with a bullish technical signal and strong earnings beat history. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though valuation multiples appear elevated with a P/E of 51.22. Recent news highlights brand campaigns and property renovations, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $342.11 implying modest upside. Risks include high debt levels and sensitivity to travel demand fluctuations. The stock offers growth exposure to hospitality recovery but requires monitoring of leverage and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
